<DOC>
	<DOCNO>NCT00057369</DOCNO>
	<brief_summary>This study evaluate new medication dose week treatment bacterial infection blood intravenous catheter ( CR-BSI ) . The primary objective evaluate efficacy safety dalbavancin treatment adult CR-BSI relative standard care treatment , vancomycin .</brief_summary>
	<brief_title>Safety Efficacy Dalbavancin Versus Vancomycin Treatment Catheter-Related Bloodstream Infections</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Dalbavancin</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>The patient his/her legally authorize representative give informed consent mean approve investigator â€™ IRB/EC ; &gt; 18 year age ; Had one central venous catheter time initial sign infection evident ; Creatinine clearance &lt; 50 mL/min ; Bilirubin &gt; 2x upper limit normal ; Treatment antibiotic effective Grampositive bacterial infection 24 hour within 48 hour study medication initiation , Prolonged antibiotic therapy CRBSI anticipate ( i.e. , &gt; 2 week )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2003</verification_date>
</DOC>